Atorvastatin 10 mg tablets recalled after failing dissolution specifications
Ascend Laboratories is recalling 141,984 bottles of Atorvastatin Calcium Tablets USP 10 mg for failed dissolution specifications.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: Scored 2 as a specification failure: the record states only that dissolution specifications were not met, without describing a health consequence or reporting injury.
Plain-English summary
Atorvastatin Calcium Tablets, USP, 10 mg, in 90-count, 500-count and 1000-count bottles, manufactured by Alkem Laboratories in India and distributed by Ascend Laboratories, are being recalled for failed dissolution specifications.
The recall covers 141,984 bottles from lots including 25141249 (expiring February 2027), 24144938, 24144868 and 24144867 (expiring November 2026), carrying NDCs 67877-511-90, 67877-511-05 and 67877-511-10. The product was distributed nationwide in the United States. The FDA has classified the recall as Class II.
The enforcement record states the dissolution failure without describing a health consequence, and reports no injuries.
Atorvastatin is a prescription medicine taken daily, so patients holding an affected lot should contact their pharmacy or prescriber about a replacement rather than stopping treatment on their own.
The recalled product
- Product
- ATORVASTATIN CALCIUM (ATORVASTATIN CALCIUM)
- Brand
- ATORVASTATIN CALCIUM
- Manufacturer
- Ascend Laboratories, LLC
- Category
- Drug — Statin
- Affected units
- 141,984
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (9)
- Lot#: 25141249
- Exp. Feb. 2027 Lot#: 24144938
- Exp. Nov. 2026 Lot#: 24144868
- Exp. Nov. 2026 Lot#: 24144867
- Exp. Nov. 2026 Lot#: 24144458
- Exp. Sep. 2026 Lot#: 24143994
- Exp. Sep. 2026 Lot#: 24142987
- Exp. July 2026 Lot#: 24143316
- Exp. July 2026
UPCs (3)
- 0367877512051
- 0367877513102
- 0367877514109
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 4 recalled by Ascend Laboratories, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same brand · ATORVASTATIN CALCIUM
- ModerateAtorvastatin 80 mg tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-22
- ModerateAtorvastatin 40 mg tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-22
- ModerateAtorvastatin 20 mg tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-22
- HighBiocon Pharma atorvastatin calcium tablets recalled for failed dissolution specifications
FDA (Drugs) · 2025-04-09
- HighPrescription atorvastatin bottles recalled for containing wrong medication
FDA (Drugs) · 2024-10-09
Same manufacturer · Ascend Laboratories, LLC
See all →- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- LowDabigatran Etexilate Capsules Recalled Over Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- ModerateDrug Recall: Dabigatran Etexilate Capsules 150 mg by Ascend Laboratories
FDA (Drugs) · 2026-07-29
- ModerateDabigatran Etexilate Capsules Recalled Over Impurity Test Failure
FDA (Drugs) · 2026-07-29
Same hazard · failed dissolution
See all →- ModerateInventia Recalls Chlorthalidone Tablets Due to Failed Dissolution Specifications
FDA (Drugs) · 2026-09-23
- ModerateMylan Recalls Prasugrel Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-09
- SevereGolden State Medical Supply Recalls Prasugrel Tablets for Failed Dissolution
FDA (Drugs) · 2026-09-09
- ModerateNovartis Recalls Diovan Valsartan Tablets Due to Failed Dissolution Specifications
FDA (Drugs) · 2026-08-19
- LowSupernus Recalls Trokendi XR Capsules for Failed Dissolution Specifications
FDA (Drugs) · 2026-07-29
Similar recalls
- ModerateAscend Recalls Atorvastatin Calcium Tablets for Failed Dissolution Specifications
FDA (Drugs) · 2019-07-31
- HighBiocon Pharma atorvastatin calcium tablets recalled for failed dissolution specifications
FDA (Drugs) · 2025-04-09
- ModeratePrescription Atorvastatin Calcium Tablets Recalled for Failed Quality Specifications
FDA (Drugs) · 2022-04-06
- ModerateDr. Reddy's Atorvastatin Calcium Tablets Recalled for Failed Impurity Specifications
FDA (Drugs) · 2021-06-23
- ModeratePrescription Drug Recall: Atorvastatin Calcium Tablets for Manufacturing Deviations
FDA (Drugs) · 2023-03-08
- HighAtorvastatin Calcium tablets recalled due to manufacturing practice deviations
FDA (Drugs) · 2023-03-08